TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01348919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered per dose and schedule specified in the arm description.
Study: NCT02537353

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metal clips
Description: The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemospray
Description: The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy Exam
Description: All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy Exam
Description: All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adrenaline
Description: The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
Study: NCT00400088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
Study: NCT02184715

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: virtual reality system
Description: The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality system
Description: The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
Study: NCT00387530

Intervention type: DRUG
Group type: OTHER
Intervention: oral sodium phenylbutyrate

Intervention type: DRUG
Group type: OTHER
Intervention: valganciclovir
Study: NCT02537353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
Study: NCT06082622

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: laxatives
Description: triple therapy of drugs, behaviour and mental axis

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: laxatives
Description: triple therapy of drugs, behaviour and mental axis
Study: NCT02153021

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J
Study: NCT02080520

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nattokinase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00658697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Starting on day 84 orally once daily until hormone therapy is completed
Study: NCT00387530

Intervention type: GENETIC
Group type: OTHER
Intervention: polymerase chain reaction

Intervention type: GENETIC
Group type: OTHER
Intervention: protein expression analysis
Study: NCT02694640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.
Study: NCT00387530

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study: NCT04544800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Splint for UADT Visualization
Description: The use of a splint to assist the patient and the surgeon with UADT procedures.
Study: NCT01888107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-acting Injectable (LAI) 25 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone LAI 37.5 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone LAI 50 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
Study: NCT04196062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoMASTER EASE Robotic system for ESD
Description: EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
Study: NCT03780608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: . Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: . Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
Study: NCT02749305

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of patient-reported outcome measures
Description: Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of patient-reported outcome measures
Description: Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
Study: NCT03508596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention for the supervisors
Description: The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
Study: NCT03315533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 milligrams (MG)
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 milligrams (MG)
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Study: NCT00170469

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPA vaccine containing alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPA vaccine containing alhydrogel
Study: NCT01282736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Response Therapy
Description: A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
Study: NCT02182596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Dose level study
Study: NCT03272685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarettes
Description: 0.4 mg nicotine/g tobacco; 9 mg tar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Content Cigarettes
Description: 15.8 mg nicotine/g tobacco; 9 mg tar
Study: NCT03850938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Kyphoplasty
Description: The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty with Rotary Cutter
Description: The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
Study: NCT01129986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaStream
Description: Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
Study: NCT00948207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Living Story
Description: Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Living Story
Description: Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Own Resources
Description: miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks.
Study: NCT04350476

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VitalConnect Vital Sign Patch
Description: This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).
Study: NCT03900312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asdzaan Be'eena' Program
Description: The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
Study: NCT04182607

Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure

Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
Study: NCT05511740

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Afternoon Radiation
Description: Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
Study: NCT03379714

Intervention type: DEVICE
Intervention: WEB aneurysm embolization system
Description: The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
Study: NCT03226457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frusemide
Description: Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frusemide
Description: Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
Study: NCT04064554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCG vaccination with MicronJet600
Description: BCG vaccination with MicronJet600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCG vaccination with conventional needle
Description: BCG vaccination with conventional needle
Study: NCT01210235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLU-FIT Program
Description: In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
Study: NCT03679013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)
Description: Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Opiate based pain regimen.
Description: Standard of care opiate based pain regimen.
Study: NCT00113893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study: NCT01966536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD133+ cells transplantation into ovarian artery of one ovary
Study: NCT01948271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris Suis Ova
Description: During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Study: NCT02332330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Study: NCT01960205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 2.5 mg a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500mg three times a day for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: lifestyle intervention for 6 months
Study: NCT00664677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terameprocol (EM-1421)
Description: Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.